FDA rejection

Pomerantz Law Firm files class action against $ATRA over alleged misstatements regarding tabelecleucel's regulatory prospects, following FDA rejections and severe stock declines.

FDA rejected Disc Medicine's bitopertin drug application on February 13, 2026, triggering a 22% stock plunge. The Rosen Law Firm investigates potential securities claims for affected shareholders.

AbbVie received FDA rejection for wrinkle drug TrenibotE over manufacturing issues, though safety and efficacy cleared. Company plans response within months.

Atara Biotherapeutics stock collapsed 97% across two FDA rejections for tabelecleucel. Class action deadline: May 22, 2026.

Corcept Therapeutics faces class action lawsuit alleging investor deception over failed relacorilant drug trial. Stock plunged 50.4% after FDA rejection.

Disc Medicine ($IRON) shares fell 22% after FDA rejected its bitopertin drug application, prompting class action investigation into securities claims.

Hagens Berman alerts $CORT investors to April 21 lead plaintiff deadline in securities fraud lawsuit over failed relacorilant drug approval and alleged FDA warning concealment.

Hagens Berman alerts $CORT investors to April 21 lead plaintiff deadline in securities fraud class action alleging concealment of FDA concerns about relacorilant ahead of rejection.

Corcept Therapeutics faces class action lawsuit for allegedly misleading investors about relacorilant's FDA prospects. Stock plummeted 50.4% after FDA rejection; investors from October 2024-December 2025 eligible to sue.

Replimune receives FDA rejection for RP1 immunotherapy despite 34% response rate in trials. Company plans layoffs, blames regulatory process.

Class action lawsuit filed against $ATRA over alleged misstatements on tabelecleucel prospects. FDA rejected drug twice; stock crashed 40-57% post-announcements.

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.

Robbins LLP files class action against $ATRA over undisclosed manufacturing issues tied to FDA rejection of lead drug tabelecleucel, citing 57% stock plunge.

Hagens Berman files class action against $CORT over alleged concealment of FDA warnings. Stock plunged 50% after December rejection, erasing $2.5B in market value.

Aldeyra Therapeutics stock plummets 71% following FDA rejection of reproxalap for dry eye disease. Class action lawsuit filed; investor deadline May 29, 2026.

Disc Medicine ($IRON) stock fell 22% after FDA rejected bitopertin program, triggering class action lawsuit investigation by Rosen Law Firm.

Hagens Berman sues $CORT over alleged concealment of FDA warnings on relacorilant. Stock crashed 50% following Complete Response Letter, erasing $2.5B in market value.

Disc Medicine faces securities probe after FDA rejects bitopertin drug; stock slides 22% on February 13, 2026.

Corcept Therapeutics shares crashed 50% after FDA rejected relacorilant application. Class action lawsuit alleges company concealed prior FDA warnings about clinical development concerns.

Corcept Therapeutics faces class action lawsuit after FDA rejected lead drug relacorilant in December. Stock fell 50.4%; investors with $100K+ losses have until April 2026 to file suit.